NCT03106740View on ClinicalTrials.gov

Evaluating the Role of Neuroinflammation in Low Back Pain

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Low Back PainBack Pain With RadiationBack Pain Without RadiationBack Pain Lower Back ChronicBack AchePain, Chronic
Interventions
DRUG

Minocycline Hydrochloride 100mg Capsule

Minocycline 100mg will be administered by mouth daily for 2 weeks

DIAGNOSTIC_TEST

Magnetic Resonance-Positron Emission Tomography Imaging

Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.

OTHER

Placebo Capsule

1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks

Trial Locations (1)

02129

Massachusetts General Hospital, Charlestown

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Marco Loggia

OTHER

NCT03106740 - Evaluating the Role of Neuroinflammation in Low Back Pain | Biotech Hunter | Biotech Hunter